Control

Sutro Biopharma Reports Second Quarter 2022 Financial Results, Business Highlights and Anticipated Milestones

Retrieved on: 
Monday, August 8, 2022 - 9:30pm
MSD, U.S. Securities and Exchange Commission, GLOBE, Investment, PDX, Security (finance), Research, Patient, Lymphatic system, Multiple myeloma, Endometrial cancer, Bevacizumab, National Medical Products Administration, Merck Group, Private Securities Litigation Reform Act, Protein engineering, Merck, IADC, DNA, Biotechnology, Safety, Lymphoid leukemia, ADC, Forward-looking statement, BCMA, ROR1, STRO, NSCLC, BMS, Neoplasm, NHL, COVID-19, Large-cell lung carcinoma, Cancer, Streptococcus, Goal, B-cell lymphoma, Fast Track, Bristol Myers Squibb, FDA, Merck Serono, IND, Company, Twitter, Depreciation, Control, NASDAQ, MM, Investor, Sutro, EMD, Serono, Pharmaceutical industry, Cryptocurrency, Fine chemical, Birth control, Vaccine, Tasly, Astellas Pharma

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the quarter ended June 30, 2022, its recent business highlights, and a preview of anticipated select milestones.

Key Points: 
  • Sutro expects to report additional data on efficacy, safety, and durability from the dose-expansion cohort, together with the design of a potential registrational study, in the second half of 2022.
  • As of June 30, 2022, Sutro held approximately 1.6 million shares of Vaxcyte common stock, with a fair value of $34.0 million.
  • Total operating expenses for the quarter ended June 30, 2022 were $47.5 million, as compared to $37.9 million for the same period in 2021.
  • Sutro Biopharma, Inc., headquartered in South San Francisco, is a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs).

Mersana Therapeutics Announces Option Agreement with GSK for the Co-Development and Commercialization of XMT-2056, an Immunosynthen ADC Targeting HER2

Retrieved on: 
Monday, August 8, 2022 - 9:02pm
U.S. Securities and Exchange Commission, ADC, Risk, Forward-looking statement, GLOBE, Senior, Breast, Technology, Private Securities Litigation Reform Act, SEC, Cancer, MRSN, Clinical trial, GSK, Conference call, HER2, Security (finance), Patient, Review, Therapy, The Boston Globe, COVID-19, Pertuzumab, Sodium-dependent phosphate transport protein 2B, B7-H4, Trastuzumab, Stomach, Safety, Control, NASDAQ, Webcast, Investor, Ovarian cancer, Conference, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Immune system, Pharmaceutical industry, Research

Under the terms of the agreement, Mersana will receive an upfront option purchase fee of $100 million.

Key Points: 
  • Under the terms of the agreement, Mersana will receive an upfront option purchase fee of $100 million.
  • Mersana also is eligible to receive up to $1.36 billion in the form of an option exercise payment and development, regulatory and commercial milestone payments if GSK exercises its option.
  • If it exercises its profit-share option, Mersana will be eligible to receive tiered royalties on net sales outside of the United States.
  • Mersanas earlier stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2).

Mersana Therapeutics Provides Business Update and Announces Second Quarter 2022 Financial Results

Retrieved on: 
Monday, August 8, 2022 - 9:04pm
U.S. Securities and Exchange Commission, Exercise, GLOBE, ORR, R, SEC, Clinical trial, GSK, Security (finance), Research, Patient, G&A, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Risk, Breast, Technology, Private Securities Litigation Reform Act, Conference call, Sodium-dependent phosphate transport protein 2B, B7-H4, Safety, Stomach, Janssen, Webcast, Ovarian cancer, Conference, ADC, Forward-looking statement, Carboplatin, HER2, Cancer, Neoplasm, Therapy, The Boston Globe, COVID-19, Maintenance, Investor, FDA, DAR, MRSN, IND, Control, NASDAQ, Platinum, Medical imaging, Fine chemical, Pharmaceutical industry

ET

Key Points: 
  • ET
    CAMBRIDGE, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the second quarter ended June 30, 2022.
  • Mersana expects to disclose initial interim dose escalation data in Q4 2022, with a primary focus on safety and tolerability.
  • Collaboration revenue for the second quarter of 2022 was $4.3 million, compared to an immaterial amount for the same period in 2021.
  • ET to discuss business updates and its financial results for the second quarter of 2022.

CareCloud Declares Dividends on Non-Convertible Series A and Series B Cumulative Redeemable Perpetual Preferred Stock

Retrieved on: 
Monday, August 8, 2022 - 2:15pm
Nasdaq, CareCloud, Cyprus Securities and Exchange Commission, Industry, Forward-looking statement, Growth, Sale, EHR, MTBC, Security (finance), Health, Company, Control, Series, RCM, Severe acute respiratory syndrome coronavirus 2, Practice management, PXM, Health information management, COVID-19, Private Securities Litigation Reform Act, Efficiency, Terminology, Risk management

Dividends on the Series A Preferred Stock and Series B Preferred Stock are cumulative and payable monthly on the 15th day of each month; provided that if any dividend payment date is not a business day, then the dividend may be paid on the next succeeding business day.

Key Points: 
  • Dividends on the Series A Preferred Stock and Series B Preferred Stock are cumulative and payable monthly on the 15th day of each month; provided that if any dividend payment date is not a business day, then the dividend may be paid on the next succeeding business day.
  • CareCloud's Series A Preferred Stock trades on the Nasdaq Global Market under the ticker symbol "MTBCP."
  • CareCloud's Series B Preferred Stock trades on the Nasdaq Global Market under the ticker symbol "MTBCO."
  • Approximately 40,000 providers count on CareCloud to help them improve patient care while reducing administrative burdens and operating costs.

NewSat North America, LLC (NewSat) Awarded Second U.S Army GTACS II Task Order

Retrieved on: 
Monday, August 8, 2022 - 1:00pm
Cyber, Multimedia, Electronics, Project, United States Army Command, Control, Communication, Computers, Cyber, Intelligence, Surveillance and Reconnaissance Center, United States Army, CEO, Computer, United States Department of Defense, NewSat, LLC, Communication, Army, Department of Defence, View, Control, US, Army of the United States, Program, Program executive officer, Online shopping, Weapon, Subcontractor, Command, Intelligence

Under this $18 million dollar TO, NewSat and Subcontractor, Ace Electronic Defense Systems, will fabricate installation kits for the integration of tactical radios on a wide range of Army platforms.

Key Points: 
  • Under this $18 million dollar TO, NewSat and Subcontractor, Ace Electronic Defense Systems, will fabricate installation kits for the integration of tactical radios on a wide range of Army platforms.
  • "NewSat has supported several logistics programs for the US Army and we are eager to deliver high-quality installation kits to enhance our troops' capabilities", said Justin Filler, CEO of NewSat.
  • "This new award with our partner Ace Electronic Defense Systems highlights our customer's trust in delivering large amounts of critical communication equipment during unprecedented times."
  • NewSat North America, LLC is a privately held, end-to-end communications company.

Utilities Global Market Report 2022: Rapid Growth in Investments in Renewable Power Generation Capacities to Drive Sector - ResearchAndMarkets.com

Retrieved on: 
Monday, August 8, 2022 - 12:58pm
Utilities, Energy, Electric power transmission, Water supply, Irrigation, Steam, Electricity generation, Growth, Investment, Asia-Pacific, Compliance, Wastewater treatment, National Grid, Control, Sewage, Nextera, Safety, Water, Natural gas, Duke Energy, Power, Digital, EDF Energy, Efficiency, Temperature, Organization, Renewable energy, Engie

The main types of utilities are water and sewage, natural gas distribution, electric power generation, transmission, and distribution.

Key Points: 
  • The main types of utilities are water and sewage, natural gas distribution, electric power generation, transmission, and distribution.
  • The rapid growth in investments in renewable power generation capacities is expected to drive the utilities market during the forecast period.
  • A large number of power generation companies are investing in renewable energy sources, especially in the USA and European countries.
  • This is expected to boost the electric power generation and subsequently drive the utilities market during the forecast period.

NEUROLENSES HAVE SIGNIFICANT IMPACT ON READING SPEED

Retrieved on: 
Monday, August 8, 2022 - 12:00pm
Headache, Industry, CEO, Population, Technology, Learning, Eye, Patient, Acceleration, Control, Neurology, Reading, Treatment, ANOVA, Tablet, Nelson–Denny Reading Test, Comprehension, OD, Optometry, SD, Phantom contour, Telescopic sight, Camera

COPPELL, Texas, Aug. 8, 2022 /PRNewswire/ -- As has been demonstrated by many studies, contoured prism has historically shown efficacy in relieving symptoms as a therapeutic offering. And new evidence suggests that there is also an opportunity to expand this technology to an even broader population focused on visual performance and productivity improvement. In a parallel arm study evaluating reading speed at baseline, after seven days of lens wear the mean (±SD) improvement in reading speed with Neurolenses was almost 70% higher than the mean (±SD) improvement in reading speed with other premium lens designs.

Key Points: 
  • In a parallel arm study evaluating reading speed at baseline, after seven days of lens wear the mean (SD) improvement in reading speed with Neurolenses was almost 70% higher than the mean (SD) improvement in reading speed with other premium lens designs.
  • NEUROLENSES' SIGNIFICANT IMPACT ON READING SPEED.
  • The mean (SD) improvement in the reading speed for Neurolenses was +20.96 words per minute, and the mean (SD) improvement in the reading speed for the Control was +12.39 words per minute.
  • ANOVA analysis revealed a statistically significant improvement in the reading speed with Neurolenses compared to the Control lens (F = 4.45; p = 0.03).

Delta Galil Strengthens Supply Chain with Infor

Retrieved on: 
Monday, August 8, 2022 - 10:00am
Nexus, Woman, Delta Galil Industries, Asparagine, Industry, Technology, Growth, Davidov, EMEA, Sale, Leadership, Creativity, ETA, Man, Review, TEL, Control, Partnership, Delta, Goal, CIO, PETA, Efficiency, ERP, Organization, Film, Online shopping, Infor

TEL AVIV, Israel, Aug. 8, 2022 /PRNewswire/ --  Infor® , the industry cloud company, today announced that Delta Galil Industries Ltd., a global leader in the design, manufacture, distribution and sale of intimates and activewear, has adopted the Infor Nexus supply chain platform. The technology will help Delta Galil improve visibility of inventory, enhancing collaboration with suppliers and customers, automating the vital plan-to-ship process, and accelerating the onboarding of new suppliers and partners.

Key Points: 
  • TEL AVIV, Israel, Aug. 8, 2022 /PRNewswire/ -- Infor , the industry cloud company, today announced that Delta Galil Industries Ltd., a global leader in the design, manufacture, distribution and sale of intimates and activewear, has adopted the Infor Nexus supply chain platform.
  • This seamless integration will increase visibility across the Delta Galil supply chain and reduce supply and capital costs.
  • "For a company like Delta Galil with many brands, retail stores, manufacturing sites and e-com websites, efficient operations and speed to market are critical," said Adi Nov, Delta Galil global CIO.
  • "Combining supply chain, operational and financial aspects into cohesive processes enables faster, more controlled growth," said Mark Illidge, Infor vice president and general manager for supply chain in EMEA.

DGAP-News: Defence Therapeutics Inc.: DEFENCE THERAPEUTICS RECEIVES U.S. PATENT COVERING ITS ADC PLATFORM TECHNOLOGY

Retrieved on: 
Monday, August 8, 2022 - 8:01am
Death, Antibody, ADC, Defense, CEO, Forward-looking statement, Catastrophic illness, Diagnosis, Technology, Cancer, Patent, Antibody-drug conjugate, Toxicity, DGAP, United States Patent and Trademark Office, Recycling, Engineering, Therapy, Cell, Company, Infection, Vaccine, News, Control, CAGR, CSE, Medicine, USPTO, USD, Security (finance), Pharmaceutical industry, BC

This new patent covers conjugated compounds permitting delivery of antibodies to the nucleus through the Company proprietary technology AccumTM.

Key Points: 
  • This new patent covers conjugated compounds permitting delivery of antibodies to the nucleus through the Company proprietary technology AccumTM.
  • "This US patent is an important milestone in protecting the commercial potential of AccumTM directly related to our ADC program.
  • Defence is expecting key ADC in vivo results in a few weeks from independent ADCs studies ongoing in Europe.
  • Defences commitment to protect the innovation is crucial as its ADC development and ADC interest applied in oncology is advancing rapidly", says Mr. Plouffe, the CEO of Defence Therapeutics.

Digital Railway Market worth $100.1 billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Friday, August 5, 2022 - 4:00pm
Knowledge, Security, Union, Intelligence, SME, Industry, Solution, CBTC, Face, European Telecommunications Satellite Organization, PTC, Efficiency, Communication, Research, Government, GEM, Control, Machine, PIS, Region, Privacy, ETSI, Health, Temperature, Organization, Rail transport, Marketing, Safety, Maintenance, EU

Train tracking solutions also help dispatchers to make better decisions as they have more accurate and real-time information about each vehicle.

Key Points: 
  • Train tracking solutions also help dispatchers to make better decisions as they have more accurate and real-time information about each vehicle.
  • The deployment and integration services ensure the proper integration of the digital railway solutions and services with various other components of the IT system.
  • The support and maintenance services aim to provide technical support to customers and deliver enhancements and upgrades to digital railway solutions.
  • Several European countries are expected to adapt to the new digital railway solutions to boost the efficiency of the existing infrastructure.